Interim guidance on the eosinophilia-myalgia syndrome.
Kilbourne
E M
EM
Centers for Disease Control, Atlanta, Georgia.
Swygert
L A
LA
Philen
R M
RM
Sun
R K
RK
Auerbach
S B
SB
Miller
L
L
Nelson
D E
DE
Falk
H
H
D002487:Centers for Disease Control and Prevention, U.S.; D004802:Eosinophilia / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D005221:Fatigue / Q000139:chemically induced; D006801:Humans; D009135:Muscular Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D010146:Pain / Q000139:chemically induced; D013577:Syndrome; D014364:Tryptophan / Q000009:adverse effects*; D014481:United States
D014364:Tryptophan